Methods and compositions for modulating splicing at alternative splice sites
AssigneeRemix Therapeutics Inc.
InventorsAnant A. Agrawal, Frederic Vaillancourt, Zaven Kaprielian, Peter Smith, Alexander S. Harding, Christopher Richer Neil, Maria Sarah Alexis
Life of this patent
Estimating the term…
Abstract
The present disclosure features bifunctional oligonucleotides and related compositions that, inter alia, modulate nucleic CA acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.
Claims122
A bifunctional oligonucleotide comprising:
- (i) an alternative splice site targeting sequence capable of binding an exonic element (e.g., 5′ splice site) within a target sequence (e.g., an RNA, e.g., a pre-mRNA or mRNA);
- and
- (ii) a spliceosome targeting sequence capable of binding a spliceosome component (e.g., a U1 snRNP).
The bifunctional oligonucleotide of any of the preceding claims, wherein the U1 snRNP is a wild type U1 snRNP or a variant or fragment thereof.
A bifunctional oligonucleotide comprising:
- (i) a nucleotide sequence capable of binding to a splice site (e.g., 5′ splice site) within exon 1 of the HTT gene, wherein the nucleotide sequence comprises a plurality of chemical modifications (e.g., a plurality of 2′OMe modifications and LNA modifications) and is between 5 and 35 nucleotides in length;
- and
- (b) a nucleotide sequence capable of binding an U1 snRNA comprising a plurality of chemical modifications (e.g., a plurality of 2′OMe modifications).
A method of modulating the production or level of a transcription product in a cell or subject comprising an exonic element (e.g., a trinucleotide expansion, e.g., a [CAG]n site) in a subject or cell, wherein:
- (i) the exonic element is flanked by a proximal splice site and a distal splice site, and
- (ii) the proximal splice site and distal splice sites are both 5′ splice sites or are both 3′ splice sites;
- comprising contacting said cell or subject with a bifunctional oligonucleotide promoting splicing at:
- (a) the distal 5′ splice site to (a-i) decrease the production or level of a transcription product comprising the exonic element or (a-ii) increase the production or level of a transcription product lacking the exonic element;
- or
- (b) the proximal 3′ splice site to (b-i) increase the production or level of a transcription product comprising the exonic element or (b-ii) decrease the production or level of a transcription product lacking the exonic element;
- thereby modulating the production or level of a transcription product comprising an exonic element (e.g., a trinucleotide expansion, e.g., a [CAG], site).
A method of modulating splicing at an alternative splice site (e.g., a flanking an exonic element, e.g., a trinucleotide expansion, e.g., a [CAG],I site) wherein:
- (i) the exonic element is flanked by a proximal splice site a distal splice site, and
- (ii) the proximal splice site and distal splice sites are both 5′ splice sites or are both 3′ splice sites;
- comprising
- (a) (i) wherein the alternative splice site is the 5′ distal splice site, promoting splicing at the 5′ distal splice site, or
- (b) (i) wherein the alternative splice site is the 3′ distal splice site, promoting splicing at the proximal 3′splice site;
- thereby modulating splicing at an alternative splice site.
A method of modulating splicing at an alternative splice site within the HTT gene in a subject or cell, wherein the HTT gene comprises a [CAG]n site and the splice site is present upstream of the [CAG]n site.
A method of treating a trinucleotide repeat expansion disease comprising modulating splicing at an alternative splice site in a subject, wherein the alternative splice site is flanking an exonic element (e.g., a trinucleotide expansion, e.g., a [CAG]n site) wherein:
- (i) the exonic element is flanked by a proximal splice site a distal splice site, and
- (ii) the proximal splice site and distal splice sites are both 5′ splice sites or are both 3′ splice sites;
- comprising
- (a) (i) wherein the alternative splice site is the 5′ distal splice site, promoting splicing at the 5′ distal splice site, or
- (b) (i) wherein the alternative splice site is the 3′ distal splice site, promoting splicing at the proximal 3′splice site;
- thereby treating a trinucleotide repeat expansion disease.
Dependencies are inferred from the claim text.